Rate increased by 17.0 percent per month before March 2020; increased 63.5 percent faster from March 2020 onward
Findings based on neuroimaging and clinical data can speed knowledge of efficacy to one week
Sex differences seen, with women experiencing greater antidepressant use and less reduction in use
Pharmacogenomic testing predicted to save the health system $956 million and bring health gains of 0.381 QALYs per patient
Reduction in need for anxiolytic drugs, antidepressants strongest for men and young and middle-aged adults
Selective serotonin reuptake inhibitor treatment tied to lower risk for maternal mental health problems and child externalizing behaviors across early childhood
No benefit seen for 52-week versus eight-week treatment for patients with bipolar I disorder with recently remitted depressive episode
Pediatricians generally document appropriate indications for starting medication and prescribe without subspecialist involvement
No adverse effects seen for antidepressant fulfillment; increases were seen in symptom screening
Improvement in well-being and remission seen with aripiprazole-augmentation of existing antidepressants